About Us
Company Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Contact Us
Our Approach
The Opportunity in China
The Everest Advantage
Partners
Pipeline
Media
Investors
News
Search
23
2021/08
Everest Medicines to Announce Half-Year 2021 Interim Results
05
2021/08
Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava
TM
for Community-Acquired Bacterial Pneumonia
29
2021/07
Everest Medicines Receives Pediatric and Rare Severe Disease Priority Review Designation from Taiwan FDA for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
20
2021/07
Everest Medicines Announces Strategic Collaboration with MediTrust Health Co., Ltd to Develop Novel Payment Solutions for Patients in China
13
2021/07
Everest Medicines Announces Strategic Collaboration with Medbanks Health Technology to Develop Innovative Healthcare Service Solutions for Patients in China
12
2021/07
Everest Medicines Announces Strategic Commercial Partnership with Global Technology Company, Tencent
05
2021/07
Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories
20
2021/05
Everest Medicines Announces China NMPA Has Granted Priority Review for Sacituzumab Govitecan-hziy in Metastatic Triple-Negative Breast Cancer
17
2021/05
Everest Medicines Announces China NMPA Has Accepted Biologics License Application for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
06
2021/05
Everest Medicines Receives Orphan Drug Designation from the Ministry of Food and Drug Safety in South Korea for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
15
2021/04
Everest Medicines Appoints Jennifer Yang as Chief Scientific Officer
14
2021/04
Everest Medicines Announces that the US FDA has Granted Licensing Partner Gilead Sciences, Inc. Accelerated Approval of Trodelvy
®
for the Treatment of Metastatic Urothelial Cancer
<<
<
1
2
3
4
5
6
7
8
>
>>
Copyright Everest Medicines 2020 云顶药业(苏州)有限公司
苏ICP备20038571号
|
Terms of Use
|
Privacy Policy
|
Disclaimers
沪公网安备 31010602006477号
a>